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Background: Magnetic sphincter augmentation (MSA) is reported to be an innovative alternative to
antireflux surgery for patients with gastro-oesophageal reflux disease. Although used in practice, little
is known about how it has been evaluated. This study aimed to systematically summarize and appraise
the reporting of MSA and its introduction into clinical practice, in the context of guidelines (such as
IDEAL) for evaluating innovative surgical devices.
Methods: Systematic searches were used to identify all published studies reporting MSA insertion. Data
collected included patient selection, governance arrangements, surgeon expertise, technique description
and outcome reporting.
Results: Searches identified 587 abstracts; 39 full-text papers were included (1 RCT 5 cohort, 3
case–control, 25 case series, 5 case reports). Twenty-one followed US Food and Drug Administration
eligibility criteria for MSA insertion. Twenty-six documented that ethical approval was obtained. Two
reported that participating surgeons received training in MSA; 18 provided information about how MSA
insertion was performed, although techniques varied between studies. Follow-up ranged from 4 weeks to
5 years; in 14 studies, it was less than 1 year.
Conclusion: Most studies on MSA lacked information about patient selection, governance, expertise,
techniques and outcomes, or varied between studies. Currently, MSA is being used despite a lack of
robust evidence for its effectiveness.
Paper accepted 11 September 2019
Published online in Wiley Online Library (www.bjs.co.uk). DOI: 10.1002/bjs.11391
Introduction
Gastro-oesophageal reflux disease (GORD) is a com-
mon condition, affecting 10–20 per cent of the Western
population1. It is associated with sequelae including Bar-
rett’s metaplasia and oesophageal adenocarcinoma, and can
have a detrimental effect on quality of life1. The primary
treatment is proton pump inhibitors (PPIs), which are
generally well tolerated1,2. Some patients, however, have
recalcitrant symptoms despite treatment and others cannot
tolerate, or do not wish to take, long-term medication2,3. In
these scenarios, antireflux surgery may be offered2,3. The
most common surgical option is fundoplication, which can
be associated with short- and long-term complications.
There is also a risk of recurrent reflux; as many as 30 per
cent of patients resume PPIs within 5 years of surgery4.
Innovative approaches to the management of refractive
or recurrent reflux have therefore been sought, and one
recent development is magnetic sphincter augmentation
(MSA) of the lower oesophagus5.
First described in 2008, MSA comprises an expandable
chain of magnetic titanium beads designed to augment the
lower oesophageal sphincter and prevent inappropriate
relaxation5. MSA is reported to be a safe, effective and rel-
atively straightforward alternative to antireflux surgery6–9.
The LINX™ system (Torax Medical, North Shoreview,
Minnesota, USA; bought by Ethicon, Johnson & John-
son, Somerville, New Jersey, USA, in March 2017) is
currently the only device marketed, receiving Conformité
Européenne (CE) marking in 2008, and Food and Drug
Administration (FDA) approval in 2012 for use in patients
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fulfilling specific criteria10. The National Institute for
Health and Care Excellence (NICE) issued guidance
in September 2012 permitting the use of MSA solely
under ‘special arrangements for clinical governance, con-
sent and audit or research’ owing to ‘limited evidence
of the safety and efficacy’11. Unlike pharmaceuticals,
there is no requirement for novel devices such as MSA to
be evaluated within the context of RCTs before they are
marketed12, meaning that it can be difficult to monitor out-
comes and risking delayed detection of long-term adverse
events.
A change in UK law around consent stipulates that, when
patients are offered new procedures or devices, there is a
requirement to provide information about the proposed
treatment and all potential alternatives so they can make
informed decisions13. This information should be based
on the best available evidence, ideally from well designed
and conducted RCTs. However, if devices are marketed on
a background of poor-quality evidence about the poten-
tial benefits and risks, without consistent and transparent
reporting of outcomes, it may be difficult for surgeons to
provide information, decide whether to offer the treatment
to patients and, crucially, to obtain fully informed consent.
This raises important issues about how best to evaluate sur-
gical innovation.
The IDEAL (Idea, Development, Exploration, Assess-
ment, Long-term follow-up) framework aims to overcome
this problem using a stepwise means of introducing and
evaluating innovative surgical procedures and devices
(IDEAL-D), with the objective of improving transparency,
evaluation and reporting of innovation in surgery, and
informing evidence-based practice12,14. Key IDEAL rec-
ommendations relate to incremental changes in study
design, clinical indications, technique standardization,
governance arrangements and outcomes, as the innovation
progresses from first-in-human to long-term follow-up.
To date, reviews of the evidence for MSA have not studied
its introduction into clinical practice, so compliance with
these IDEAL guidelines for evaluating innovative surgical
procedures and devices is unknown14. This study therefore
aimed to summarize and appraise the reporting of studies
of MSA, to understand how this innovative procedure has
been introduced and evaluated in relation to the IDEAL
recommendations.
Methods
A systematic review was undertaken to identify all pub-
lished studies reporting MSA insertion. The review was
conducted in line with the PRISMA statement15. Methods
were based on those described previously14.
Search strategy and study selection
Searches were undertaken in MEDLINE, Embase,
CINAHL (Cumulative Index to Nursing and Allied
Health Literature), the Cochrane Library, Web of Science
and BIOSIS databases, from inception to January 2019.
Searches consisted of subject headings and text words,
combining terms for ‘magnetic sphincter augmentation’
with ‘gastro-oesophageal reflux disease’ using the Boolean
operator ‘AND’ (Table S1, supporting information).
Study eligibility
Searches were limited to studies in humans, written in
English. All primary research study designs (such as case
reports, case series and comparative studies) were eligi-
ble for inclusion. Where systematic reviews were identi-
fied, reference lists were cross-checked to ensure that all
eligible studies were included. Presentations and confer-
ence abstracts were excluded because of the high probabil-
ity of incomplete data. Studies reporting solely on device
removal were excluded. Search results were deduplicated.
Identification and selection of papers
Titles and abstracts were screened independently by two
authors. The full-text versions of papers retained after
title and abstract screening were assessed further for eli-
gibility. Disagreements were first discussed between the
reviewers, and any unresolved conflicts referred to the
wider study team. Reference lists of included papers were
searched manually for additional relevant articles. Data
from full-text papers were extracted independently by at
least two assessors.
Data collection
Data collection was based on IDEAL recommendations14,
and included information about general study characteris-
tics, patient selection, regulatory and governance arrange-
ments, operator and centre expertise, technique description
and outcome reporting14. Outcome data were extracted
from papers reporting follow-up of initial studies included
in the review to acquire information about long-term out-
comes; however, other data were not included to avoid
double-counting of results.
General study characteristics
The study design, year and journal of publication, country
of origin, and number of participating centres and patients,
were extracted. The timing of publication of studies in rela-
tion to FDA approval was also recorded. If studies involved
a comparator group, eligibility criteria were compared with
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those for MSA, including any matching at baseline or statis-
tical analyses to account for differences. Risk-of-bias assess-
ments were undertaken for RCTs16.
Patient selection
Study-specific inclusion and exclusion criteria for undergo-
ing MSA insertion were documented, and compared with
the criteria approved by the FDA in 2012. If different crite-
ria were used, these were recorded along with any rationale.
Information regarding those who were eligible to undergo
MSA insertion, but did not have the procedure, was also
collected.
Regulatory and governance arrangements
Reporting of information about governance approvals (for
example, ethics committees, Institutional Review Boards
(IRBs) and clinical effectiveness committees) was docu-
mented. Articles were assessed for whether patients were
informed specifically about the innovative nature of MSA.
Details of any funding from the manufacturer or other
potential conflicts of interest were also noted.
Operator and centre expertise
Details of the types of centre and number of surgeons
undertaking MSA insertion were recorded. Reports of sur-
geon and team experience with the new procedure, includ-
ing any details of the learning curve and how it was
accounted for, were extracted.
Technique description
All descriptions of the techniques used to insert MSA were
extracted verbatim and assessed using a typology, which
allows systematic deconstruction of an intervention into
its individual components and steps17,18. Descriptions of
each component (such as incisions, dissection, device inser-
tion and reconstruction) were tabulated chronologically, to
identify whether: there was clear reporting of what had
been performed; modifications occurred over time; and the
technique had stabilized.
Outcome selection, measurement and reporting
All outcomes were extracted and categorized into groups:
clinical (a clinician’s or researcher’s assessment of symp-
toms or signs)19; patient-reported (a report of the sta-
tus of a patient’s health condition that comes directly from
the patient, without interpretation of the patient’s response
by a clinician or anyone else)20; process (the specific
steps that lead to a particular outcome)21; cost and other
economic; and adverse events (an untoward medical occur-
rence as a result of the use of the device)22. The rationale
for device removal and techniques used when removal was
required were also documented.
In addition to recording details of reporting, adverse
event and process data were summarized by calculating the
range of rates for each outcome.
Data synthesis
Results were summarized in a narrative synthesis, with
descriptive statistics where appropriate. Comparisons were
made between studies undertaken before and after market-
ing approval to establish compliance with FDA-approved
criteria. Because the study did not aim to draw conclu-
sions about the effectiveness of MSA over other treatments,
meta-analyses were not performed.
Results
Characteristics of included studies
Systematic searches identified 974 papers and, after remov-
ing duplicates, 587 abstracts were screened (Fig. 1). A total
of 39 full-text papers6,10,11,23–58, published between 2008
and 2019, were finally included. The 39 articles consisted
of one RCT, five comparative cohort studies (2 prospec-
tive and 3 retrospective), three comparative case–control
studies, 25 case series (14 prospective, 11 retrospective)
and five case reports (Fig. 2). Four papers23–26 reported
longer-term outcomes from earlier studies. This review
therefore presents the results of the remaining 35 papers
in detail unless specified otherwise.
Two papers were published before FDA approval. The
first10 was reported to be a feasibility study aimed at
demonstrating the safety and efficacy of MSA, and the
second24 reported 1- and 2-year follow-up of the initial
study.
Seventeen studies were reported from a single centre.
Thirty-three studies included at least one author who had
published two or more articles on MSA. Nine studies
(1 RCT, 5 cohort and 3 case–control studies) included
a comparator group (Tables 1 and 2), although only one
was randomized. Of these, seven compared MSA with
antireflux surgery, one27 compared different types of dis-
section technique for MSA, and the RCT28 compared MSA
with PPIs. Five, including the RCT, reported differences
in patient baseline demographics, including hernia size,
obesity, age, DeMeester score and disease severity, which
were not accounted for in analyses. Although four reported
‘matched’ controls, there were differences in demographics
in three29–31,33.
The only RCT included 152 patients, randomized to
receive PPI (102) or MSA (50) in a 2 : 1 ratio across 21 US
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Table 1 Details of nine studies comparing magnetic sphincter augmentation with an alternative technique
Eligibility criteria
Reference Study design No. of patients Comparator MSA Comparator
Louie et al.44 Cohort* 66 (34 MSA) LNF FDA criteria FDA criteria
Sheu et al.29 Case–control* 24 (12 MSA) LNF Previous ARS, hiatus hernia >2 cm,
dysmotility, allergy to device, need
for future MRI
n.r.
Riegler et al.45 Cohort 249 (202 MSA) LNF FDA criteria plus hernia >3 cm,
Barrett’s and stage C or D
oesophagitis
FDA criteria plus hernia
>3 cm, Barrett’s and stage
C or D oesophagitis
Reynolds et al.32 Case–control* 100 (50 MSA) LNF FDA criteria FDA criteria
Asti et al.33 Cohort 238 (135 MSA) LTF FDA criteria FDA criteria
Warren et al.30 Cohort* 415 (201 MSA) LNF FDA criteria FDA criteria
Reynolds et al.31 Case–control* 119 (52 MSA) LNF n.r. n.r.
Tatum et al.27 Cohort* 182 (all MSA) Surgical
technique




Bell et al.28 RCT 152 (50 MSA) PPI FDA criteria FDA criteria
*Retrospective. MSA, magnetic sphincter augmentation; LNF, laparoscopic Nissen fundoplication; FDA, Food and Drug Administration; ARS, antireflux
surgery; n.r., not reported; LTF, laparoscopic Toupet fundoplication; PPI, proton pump inhibitor.
Table 2 Differences in baseline characteristics in studies comparing magnetic sphincter augmentation with an alternative technique
BMI (kg/m2) Age (years) GERD-HRQL score DeMeester score Hernia size (cm)
Reference MSA Comparator MSA Comparator MSA Comparator MSA Comparator MSA Comparator
Louie et al.44 27 30 54 47 n.r. n.r. n.r. n.r. 1⋅4 1⋅5
Sheu et al.29 26⋅6 26⋅6 39⋅3 43⋅8 n.r. n.r. n.r. n.r. n.r. n.r.




n.r. n.r. 1⋅6%>3 cm 45⋅7%> 3 cm
Reynolds et al.32 26⋅4 26⋅7 53 54 19⋅7 18⋅8 n.r. n.r. 1⋅5 1⋅6
Asti et al.33 23⋅9 25⋅1 44 50 21⋅0 19⋅7 31⋅4 37⋅6 2 2
Warren et al.30 32 40 54 52 21 19 34 39 n.r. n.r.
Reynolds et al.31 26 27 53 53 17 19 n.r. n.r. n.r. n.r.
Tatum et al.27 26⋅8 27⋅8 55⋅3 63⋅1 n.r. n.r. 39⋅9 79⋅3 0⋅64 2
Bell et al.28 28 28 46 46 23⋅5 25⋅0 40⋅3 30⋅9 58%<3 cm 49%< 3 cm
GERD-HRQL, gastro-oesophageal reflux disease – health-related quality of life; MSA, magnetic sphincter augmentation; n.r., not reported; GORD,
gastro-oesophageal reflux disease.
centres. It concluded that patients should be considered
for MSA rather than increased PPI doses; however, the
overall risk of bias was unclear because no information
was provided about the randomization process, allocation
concealment or attrition.
Patient selection
All studies involved adult patients aged over 18 years.
Twenty-one followed the FDA eligibility criteria for MSA
insertion10. Seven, comprising a total of 427 patients and
published after FDA approval, extended these criteria to
include patients with a hiatus hernia greater than 3 cm34,35
or previous gastrointestinal surgery36–40, to assess whether
the device could be used in this population.
Three articles provided information about patients who
were recruited but did not receive MSA. Reasons included:
insurance requirements, patient preference, allergy to
device metals, the potential future need for MRI (initially,
this was a contraindication to MSA insertion26), or con-
version to conventional antireflux surgery owing to more
severe disease at operation than expected.
Regulatory and governance arrangements
Twenty-six studies reported that ethical approval had been
obtained (IRB in 23, ethics committee in 3). Twelve studies
were funded by the manufacturer, and 24 stated a conflict
of interest in that some or all authors worked at the device
company. Only 14 explicitly documented obtaining patient
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Smith et al.42 Surgeons’ previous
experience




Lipham et al.47 ‘Proficiency in performing laparoscopic Nissen fundoplication and comfortable working at the
oesophago-gastric junction’
Bell et al.28 ‘Trained and experienced in MSA’
Kuckelman et al.39 Training requirements ‘All surgeons had completed the training and certification process for MSA placement, including
didactics, live case observations, and then proctoring on initial cases’
Louie et al.48 ‘All participating study centres were required to have undergone training to implant the device
and completed a minimum of five LINX™ implants’
GORD, gastro-oesophageal reflux disease; MSA, magnetic sphincter augmentation.
consent for study participation; a further six stated that
consent was not needed given the study’s retrospective
nature.
One premarket study10 documented specific discussions
with patients regarding the innovative use of MSA: ‘each
patient was informed about the investigational nature of
the trial and received detailed information about the study
protocol’. One further paper38 reported that the authors
‘advised patients about the novelty of the approach’. None
of the seven articles that extended the inclusion criteria off
licence to patients outside the FDA-approved guidelines
reported discussing this with patients, although ethical
approval was obtained for all seven.
Operator and centre expertise
None of the studies provided any information about the
surgical learning curve. Fifteen stated the number of
surgeons performing MSA procedures (range 1–4). Seven
reported entry criteria for participating surgeons (Table 3).
Two studies reported that participating surgeons received
training in the use of MSA. A further study reported that
specific experience with MSA was required, but did not
quantify what this comprised. The remaining five reported
only that surgeons were required to have experience with
antireflux surgery in general. None reported information
about the expertise or training of the wider surgical team
(nurses and anaesthetists). Although three studies stated
that their hospitals were ‘high volume’ and one a ‘specialist
reflux centre’41, no other information about caseload was
provided.
Technique description
Eighteen studies reported at least some information
about the technique of MSA insertion, and a further
nine cited one or more of these articles (Table S2,
supporting information). Although the first published
study10 documented the procedure in detail, no study
described every component. Technical details were
reported about the incisions (8 studies), hiatal dissec-
tion (18), device insertion (18) and crural repair (9).
However, these descriptions were heterogeneous, using
different wording and describing different anatomical
structures. It was therefore difficult to determine whether
the procedure or any of its components had evolved with
time or whether they had stabilized.
With regard to the dissection technique, the need to
identify the vagal trunk, access the retro-oesophageal win-
dow and perform ‘minimal hiatal dissection’ was reported
in seven, five and seven studies respectively, although the
latter was not defined. One study27 aimed to undertake a
comparison of ‘minimal hiatal dissection’ with ‘planned
obligatory dissection’. During the study, however, this
comparison was abandoned and all subsequent patients
underwent obligatory hiatal dissection, with no explanation
of why this occurred.
Of the studies providing details about device insertion,
six reported how the sizing device should be inserted
and three documented the required tightness around the
oesophagus. Further information about the insertion tech-
nique varied between studies; for example, five reported the
device location as between the posterior vagus and oesoph-
agus, and two the retro-oesophageal window. One study
(100 patients)6 reported using a modified version of MSA,
whereby the first 30 patients received a first-generation and
the rest a second-generation device. Differences between
the devices were described as the ‘use of a clasp instead
of a suture to close the ring’ and a ‘laparoscopic sizing
tool’ instead of a ‘colour-coded sizing device’, although
there was no further information and no rationale for the
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modification was provided. There was no documentation
to suggest that patients were made aware of this change
of device or that ethical approval was sought. No other
studies documented which generation of device was used.
Eleven studies reported that crural repair was undertaken
at the discretion of the surgeon, and technical information
was included in nine. Of these, two described a posterior
cruroplasty using ‘a permanent suture’ and ‘with one or
two sutures’, whereas seven stated only that ‘posterior
cruroplasty’ was undertaken. Four studies documented a
rationale for crural repair: ‘…when the hiatus appeared
patulous or a sliding hernia was present’ 6,42, and ‘if hiatal
hernia visible after posterior dissection of hiatus that kept
the phreno-oesophageal membrane intact’31,32.
Outcome selection, measurement and reporting
Outcome reporting from all 39 papers is summarized
in Table 4. Thirty-eight different outcomes were reported
across all studies. No single outcome was measured in all
studies. No study provided a rationale for the outcomes
selected. Duration of follow-up ranged from 4 weeks to
5 years; this was not reported in one study. Five-year data
were available from two studies and the duration of follow
up was less than 1 year in 14.
Clinical outcomes
Objective clinical outcomes were reported in 25 stud-
ies. These included data from DeMeester scores (7 stud-
ies), manometry (4), oesophageal pH measurements (10),
oesophagogastroduodenoscopy (13) and barium swallows
(7). Fifteen of the 25 studies reported obtaining more
than one of these objective outcomes. These assessments
were undertaken at variable times after surgery, ranging
from 1 day to 3 years. Three studies performed these tests
beyond 1 year after operation. The objective clinical data
were infrequently correlated with the patient-reported out-
comes reported below.
Patient-reported outcomes
The validated gastro-oesophageal reflux disease
health-related quality of life (GERD-HRQL) ques-
tionnaire was used in 31 studies. Baseline questionnaires
were administered before operation in all 31 studies and at
various other time points, ranging from 10 days to 5 years
after surgery. Only five studies reported use of the ques-
tionnaire after a year. Other assessment measures included
a Foregut Symptom Questionnaire (4 studies), Respiratory
Index Score (1), Quality of Life in Reflux and Dyspepsia
score (1) and Modified Dakkak dysphagia severity score
(1). Five remaining studies reported patient-reported out-
comes, including incidence of dysphagia, change in reflux,










Device removal 27 0⋅5–8⋅3
Device erosion 8 0⋅1–1⋅2
Need for dilatation 22 2–67
Readmission to hospital within 30 days 13 1⋅3–5⋅4
Mortality 3 0
Clinical
DeMeester score 7 –
Manometry 4 –
Oesophageal pH testing 10 –
Oesophagogastroduodenoscopy 13 –
Barium swallow 7 –
Proton pump inhibitor use 25 –
Process
Duration of operation (min) 16 23–184†
Duration of hospital stay (days) 13 0–3†
Patient-reported outcomes
GERD-HRQL score 31 –
Other validated patient-reported outcomes 7 –
Non-validated patient-reported outcome 5 –
Economic
Costs associated with device 1 –
*Unless indicated otherwise; †values are median (range). GERD-HRQL,
gastro-oesophageal reflux disease – health-related quality of life.
gas-related symptoms and symptoms of odynophagia, but
did not define these or use a named questionnaire.
Process outcomes
Operating time and duration of hospital stay were reported
in 16 and 13 studies, respectively.
Cost and economic outcomes
One study reported an economic outcome: overall hospital
charges associated with device insertion.
Adverse events
Twenty-two studies reported the need for postoperative
oesophageal balloon dilatation for dysphagia or odynopha-
gia, eight described cases of device erosion into the
oesophagus, and 13 readmission to hospital (for reasons
including dehydration, dysphagia, pain, nausea and pul-
monary embolus). No intraoperative complications were
reported in any paper.
Device removal
Of the 27 studies reporting the need for device removal
(total 84 patients), the timing ranged from 21 days to
© 2019 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2020; 107: 44–55
on behalf of BJS Society Ltd.
Magnetic augmentation of the lower oesophageal sphincter for gastro-oesophageal reflux disease 51
47 months after insertion. No prespecified criteria or ratio-
nale were provided. Reasons for device removal were
reported in all studies, and included erosion, migration,
development of oesophageal cancer, ongoing refractory
symptoms, the need for MRI and patient preference. The
surgical approach to device removal was poorly docu-
mented in these studies, and included laparoscopic, endo-
scopic and laparoendoscopic techniques.
Discussion
This comprehensive review of the reporting of an
innovative surgical device – MSA of the lower oesopha-
gus – summarizes information from 39 studies published
between 2008 and January 2019. Only one small RCT
was identified; most studies were case studies or case
series with serious shortcomings. Of the nine compara-
tive studies, including one RCT, eight were limited by
different selection criteria and unmatched patients at base-
line. Information about ethical approval, patient consent
and conflicts of interest was often missing. Many studies
reported using MSA for indications outside the current
FDA regulations. Reporting of the technical aspects of
device insertion was either lacking or varied between
studies, making it difficult for surgeons to replicate the
technique and learn from others’ experiences. Currently,
therefore, MSA is being used in clinical practice despite a
lack of robust evidence to support its effectiveness, poten-
tially placing patients, surgeons and healthcare providers
at risk. Although some guidance for evaluating innova-
tive surgical procedures and devices is available (IDEAL
recommendations), it was not followed. Pilot work is
now required to address the aforementioned issues and
enable an RCT comparing MSA with current treatments
to be designed optimally, to inform decision-making
and patient care. Moreover, a registry to monitor device
insertions, document long-term outcomes including
adverse events, record surgeon experience and allow safe
widespread adoption of the device into clinical practice,
is required.
The Royal College of Surgeons of England has urged
the government to ‘act urgently to reform the lax regula-
tion system governing medical devices, including a com-
pulsory registry of all new implants’12,59. Such a system
would need to strike a balance between avoiding bur-
den and encouraging the development of well founded
evidence on safety and efficacy12,59. There has been a
recent call for new surgical procedures and implants to
be tested in RCTs before being made routinely avail-
able, in line with IDEAL recommendations and existing
pathways for introducing pharmaceutical products12. In
the UK, the Medicines and Healthcare products Regula-
tory Agency60 regulates medical devices with the aim of
ensuring that they are safe and efficacious. The type of
study required to achieve approval is not specified, but
the majority do not include a control group, despite the
Royal College calling for more RCTs to be undertaken
and encouraging surgeons to use IDEAL guidance59. In the
USA, invasive devices are now subject to a pivotal clinical
study as part of the FDA’s premarket approval pathway12.
Although MSA did undergo a pivotal study, subsequent
publications failed to build on its findings and long-term
outcomes have not been established, particularly when
compared with current treatments (PPIs and antireflux
surgery).
This is concerning in the context of recent high-profile
devices that have later caused serious health problems
despite complying with regulatory processes. One such
example is transvaginal mesh, which is no longer offered
routinely as the result of an independent review61. Another
example is robotic surgery. Although this has been intro-
duced rigorously in some surgical disciplines (robotic
prostatectomy has been endorsed by NICE for centres
performing more than 150 procedures per year), such
evaluation has not been applied uniformly. Conversely, a
recent review62 conceded that, despite a lack of evidence
to support any benefit, cardiac surgery ‘represents one
of the largest markets in the field of robotic surgery’,
and the first robotic mitral valve replacement in the UK
resulted in the death of the patient63. Following this,
guidance regarding the clinical governance, oversight and
infrastructure required when introducing new innovations
has been published. The guidance reinforces the respon-
sibilities of surgeons and surgical societies in arranging
appropriate training and mentorship, and submission of
data to national registries, thereby placing patient safety
at the core64. Another example of a device that was intro-
duced before full evaluation – and subsequently removed
from practice – is the Angelchik prosthesis. Similar to
MSA, it gained popularity as a solution to GORD in the
1980s because of its technical simplicity65. Although data
from initial non-randomized studies were promising, an
RCT was stopped prematurely owing to adverse events,
and long-term follow-up detected erosions and migrations
necessitating reoperation in 25 per cent of patients66. As
a result, use of the device was almost entirely abandoned
by the early 2000s, by which time over 25 000 had already
been inserted.
Despite this, MSA continues to be used across the
world and over 3000 device insertions were undertaken in
the USA between 2012 and 201643. A registry that was
funded and sponsored by the device manufacturer existed
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until 2016. However, this did not include all patients
and follow-up was limited to 3 years because it closed
prematurely for unknown reasons. Without registries to
monitor outcomes of new devices, there can be delays
in understanding the short- and long-term risks of new
devices and procedures67.
This study has tracked the introduction and evolution of
MSA from the first published description to the present
day. Despite this, however, there are limitations. Out-
comes were not analysed in depth and meta-analyses were
not undertaken. Exclusion of non-English language papers
may mean that important additional findings were missed.
Data were extracted verbatim, and the authors assumed
that if something was not documented, it did not happen;
authors were not contacted individually for further infor-
mation. It is also possible that the device is used much more
widely and other cases have not been published. A final
limitation is that one paper was published before IDEAL
was introduced in 2009 (and therefore could not have fol-
lowed these guidelines rigorously), and a further 16 were
published before publication of the updated IDEAL-D
framework specific for surgical devices in 2016. More work
is needed to establish why the IDEAL guidance has not
been followed; despite this, the fundamental principles of
IDEAL are not new concepts and form the basis of good
research.
This in-depth analysis of reporting of an innovative
invasive procedure corroborates existing evidence12 that
surgical procedures are often poorly evaluated before
implementation in clinical practice. The long-term safety
of MSA has not been sufficiently demonstrated in the
existing 39 published studies owing to inconsistent report-
ing of outcomes, particularly those detailing long-term
follow-up. There is a lack of standardized, transparent
reporting of how the MSA device should optimally be
inserted, making adoption into practice difficult and ham-
pering comparisons between studies. There is a need for
robust assessment and reporting to improve the rigour
with which innovative surgical procedures are evaluated,
to optimize transparency, maximize patient benefit and
reduce harms.
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Editor’s comments
What have we learned from the past? Not much, according to this study by Kirkham et al. The surgical community
falls short in the proper evaluation of new surgical devices before implementation in clinical practice. We have to do
better in terms of informing patients on experimental treatments and being critical on new technologies. On the other
hand, we want to make surgery safer, more accessible and improve the outcomes, and technological improvements
are needed to achieve these goals. However, I share the authors’ conclusion that ‘magnetic sphincter augmentation
is being used in clinical practice despite a lack of robust evidence to support its effectiveness, placing surgeons and
patients at risk’. There is a clear need for international registries that evaluate indications and outcomes of new devices
and techniques. National surgical bodies and governments should support these registries so they are independent of
the industry/companies and surgeons involved in the manufacturing and promotion of new devices, because there will
always be a conflict of interest.
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